Search results for: NICE

A Dose of Economics

…runs through every episode: what can health economics really bring to the most pressing problems in healthcare today?   Topics include:  NICE decision-making and cost-effectiveness thresholds  AI and its role in health…

Mid-year health check: policy, pricing & what’s coming

17 June 2026, 2:00pm

…Favored Nation (MFN) pricing and its global ripple effects to rare disease access, the recent HEMA report publication and adopting broader value perspectives in HTA, and the new NICE threshold…

Patrick Hopkinson

14 May 2026

…he served as a NICE Appeal Panel member for 10 years. Previously he worked at GSK in Global and Country roles and as a Clinical Oncology Pharmacist in the UK…

Haider Shamsi

23 June 2026

…served as a Technical Lead at the National Institute for Health and Care Excellence (NICE) in the United Kingdom, leading assessments of pharmaceuticals, medical devices, diagnostics, and innovative health technologies….

Workshop on HTA and Regulatory Review

13 May 2010

Tensions between broad access to new medical technologies and efforts to contain health care costs are perennial. In recent years, this has become evident in the uncomfortable discontinuities that can…

Australia’s Publicly Funded Vaccines Market

1 December 2010

The OHE recently published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by the Federal German Ministry of…

Overview of the Economics of the Market for Medicines in the UK

29 March 2012

OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2012 activities, he recently gave a comprehensive lecture on…

Spotlight on OHE: Value Based Pricing and New Technologies

31 December 2012

The OHE has been very active in conceptualising approaches incorporating a broader assessment of the elements of value (often called “value based pricing” or “VBP”), as its publications to date…

New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds

31 January 2013

Just out in the International Journal of Technology Assessment in Health Care is an important new study that reviews appraisals of breast cancer and colorectal cancer medicines by HTA agencies…